Ovarian Cancer

Durvalumab plus tremelimumab in combination with neoadjuvant chemotherapy did not yield any major adverse effects in patients with newly diagnosed advanced ovarian cancer in the phase 2 KGOG3046 trial.

Vadim Gushchin, MD, says that treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of negatively impacting health-related quality of life in ovarian cancer.

Data from the phase 2 INNATE trial indicate that pimivalimab plus JTX-8064 also appears to be well tolerated in patients with platinum-resistant ovarian cancer.

Maintenance olaparib plus bevacizumab may improve survival in patients with high-grade ovarian cancer regardless of BRCA mutation location, according to a subgroup analysis of the PAOLA-1/ENGOT-ov25 trial.

Treatment with avutometinib and defactinib in patients with low-grade serous ovarian cancer resulted in a positive objective response rate.

Findings from the phase 3 NORA study identified a numerically longer median overall survival among patients with platinum-sensitive recurrent ovarian cancer treated with maintenance niraparib regardless of BRCA mutation status.

The first-in-class Heat Shock Factor 1 pathway inhibitor NXP800, the subject of an ongoing phase 1 dose-escalation study, has been granted a Fast Track designation for the treatment of platinum-resistant ovarian cancer by the FDA.

A longer, 30-month treatment duration with bevacizumab did not improve outcomes over the standard 15-month treatment duration in patients with newly diagnosed ovarian cancer.

The VENTANA FOLR1 RxDx Assay has received approval from the FDA for identifying epithelial ovarian cancer in patients who may be eligible for treatment with mirvetuximab soravtansine-gynx.

The FDA has granted mirvetuximab soravtansine-gynx an accelerated approval for the treatment of patients with folate receptor-α-positive platinum-resistant ovarian cancer based on results from the phase 3 SORAYA study.

Despite inconclusive efficacy results regarding the use of pembrolizumab plus epacadostat in patients with recurrent clear cell ovarian carcinoma, rapid accrual to the trial reveals an unmet need in this cancer subset.

Data from the phase 3 ATHENA-MONO study indicated that maintenance rucaparib yielded progression-free survival benefit vs placebo across all subgroups in a population of patients newly diagnosed ovarian cancer, according to David O’Malley, MD.

Patient-reported outcome data from the phase 3b OReO/ENGOT-ov38 trial showed no significant effect on quality of life following rechallenge with maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer.

Results from the phase 3 ATHENA-MONO study suggest that rucaparib could serve as a promising first-line maintenance treatment option in newly diagnosed ovarian cancer.

Results from a Korean study presented at 2022 IGCS showed that the level of CA-125 at different timepoints during neoadjuvant chemotherapy may help clinicians decide which patients with high-grade serous ovarian cancer should undergo interval debulking surgery.

PARP inhibitors like rucaparib should be considered to treat all kinds of patients, including those who have deleterious mutations and HRD, according to Amit Oza, MD, MBBS, FRCPC.

PARP inhibitors such as rucaparib appear to garner the most benefit in the early maintenance setting in patients with ovarian cancer who have less advanced disease and less heterogeneity, according to Amit Oza, MD, MBBS, FRCPC.

Olaparib and bevacizumab has been approved in China as a frontline maintenance treatment for patients with advanced homologous recombination deficiency–positive ovarian cancer based on results from the phase 3 PAOLA-1 trial.

A supplement biologics license and a Type II variation were submitted to the FDA and European Medicines Agency, respectively, for first-line rucaparib in patients with advanced ovarian cancer.

Patients with newly diagnosed ovarian cancer with or without a high risk of progression experienced a progression-free survival benefit from treatment with maintenance rucaparib compared with placebo regardless of molecular characteristics.

After 7 years of follow-up, results from the phase 3 SOLO1/GOG-3004 trial support maintenance olaparib to achieve long-term remission in women with newly diagnosed advanced ovarian cancer.

Results of the phase 3 ARIEL4 trial comparing rucaparib vs chemotherapy for patients with relapsed ovarian cancer and deleterious BRCA1/2 mutations were presented at 2022 ESMO and raised questions about optimal sequencing of PARP inhibitors in this setting.

The final analysis of the PAOLA-1/ENGOT-ov25 trial confirmed the benefit of olaparib plus bevacizumab as maintenance therapy following frontline treatment in women with HRD-positive advanced ovarian cancer.

Results from the phase 3 ICON8 trial showed patients with epithelial ovarian cancer did not experience an overall survival or progression-free survival benefit with weekly dose-dense chemotherapy in the first line compared with 3 times weekly.

The primary end points of progression-free survival and overall survival were not met in the phase 3 OVAL trial assessing ofranergene obadenovec for patients with platinum-resistant ovarian cancer.

Progression-free survival and overall survival were enhanced with the use of bevacizumab plus first-line chemotherapy in ovarian clear cell carcinoma.

A neoadjuvant and postsurgical treatment regimen involving ruxolitinib and chemotherapy appeared to boost progression-free survival in patients with stage III and IV ovarian cancer.

The ATHENA-MONO trial showed a significant improvement in progression-free survival when patients with platinum-sensitive ovarian cancer were treated with maintenance rucaparib vs placebo in the first-line setting, regardless of HRD status.

Results from the phase 3 SORAYA trial supported the acceptance of a biologics license application for mirvetuximab soravtansine under priority review by the FDA for patients with folate receptor α–high platinum-resistant ovarian cancer.

Real-world practice patterns with bevacizumab for patients with ovarian cancer differed greatly from published clinical trial data.